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SUMMARY
The human endometrium undergoes to a complex series of proliferative and secretory 
changes in each menstrual cycle and displays only a short period of receptivity, known 
as the “window of implantation”, necessary for the implantation of the blastocyst in the 
uterus. The implantation process occurs in a sequential manner, leading to the establish-
ment of pregnancy. Morphofunctional changes during this period may prevent or hinder 
the implantation. For this reason, the study of the endometrium at this stage is important 
for the improvement of therapies that may interfere with the mechanisms involved in 
maternal-embryonic interaction. Several gynecological disorders, including polycystic 
ovary syndrome (PCOS), are associated with decreased fertility and uterine receptivity. 
In spite of recent advances in assisted reproduction techniques, allowing the selection of 
high quality embryos, the implantation rate remains low and has not increased enough 
in recent decades. This article aims at reviewing the endometrial aspects of the “window 
of implantation” in women with polycystic ovary syndrome, focusing mainly on adhe-
sion molecules. For that purpose, we analyzed 105 articles published in journals indexed 
in PubMed in the last 50 years (up to May 2011). In conclusion, the endometrial recep-
tivity seems to be the major limiting factor for the establishment of pregnancy in a large 
number of gynecological diseases, including PCOS, and treatment to improve implanta-
tion rates is likely to be taken towards this direction.
Keywords: Endometrium; embryo implantation; cell adhesion molecules; infertility, 
female.
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INTRODUCTION
The polycystic ovary syndrome (PCOS) was first described 
by Stein and Leventhal in 1935, characterized by the associa-
tion between polycystic ovaries and amenorrhea, infertility, 
hirsutism and obesity1. It is estimated to affect approximate-
ly 5% to 7% of women of reproductive age, representing the 
most frequent cause of anovulatory infertility2,3. 
The diversity of PCOS clinical features has led to the 
creation of three consensuses to establish diagnostic crite-
ria for this syndrome. The first was the meeting of the Na-
tional Institutes of Health (1990), which defined as PCOS 
diagnostic criteria the presence of clinical or laboratory 
hyperandrogenism and spaniomenorrheic cycles or amen-
orrhea (fewer than six menstrual cycles per year), provid-
ed that other alterations such as Cushing’s syndrome, hy-
perprolactinemia, adrenal enzyme deficiency and thyroid 
disorders had been ruled out4.   
The second was the consensus of Rotterdam (2003), 
carried out by the European Society for Human Reproduc-
tion and Embryology (ESHRE) and the American Society 
for Reproductive Medicine (ASRM), which established as 
diagnostic criteria: spaniomenorrheic cycles or amenor-
rhea (chronic anovulation), clinical or biochemical signs 
of hyperandrogenism and the presence of polycystic ova-
ries (identified by ultrasonography), with at least two of 
three criteria being necessary to define the diagnosis 
of PCOS5. 
The third consensus was proposed by the Androgen 
Excess and PCOS Society (AE-PCOS) in 2006, which es-
tablished as diagnostic requirements: hyperandrogenism 
(hirsutism and/or hyperandrogenemia), ovarian dysfunc-
tion (oligo-/anovulation and/or polycystic ovaries), while 
ruling out other causes of androgen excess6,7. Thus, based 
on the ESHRE/ASRM (2003) and AE-PCOS Society6 cri-
teria, the wide spectrum of signs and symptoms that are 
observed in these patients can be identified8. 
The pathophysiology of PCOS has puzzled gynecolo-
gists and endocrinologists for many years and is very dif-
ficult to be defined. The clinical features of PCOS dem-
onstrate a disorder of follicular development resulting in 
chronic anovulation, where the endocrine environment is 
characterized by a state of equilibrium in which the con-
centrations of gonadotropins and sex steroids have little 
variation in comparison with the cyclic pattern of hormone 
concentrations that occurs during the normal cycles9. 
PCOS usually displays increased serum concentrations 
of luteinizing hormone (LH) in 60% of cases, low levels of 
follicle stimulating hormone (FSH) and increased 
LH/FSH ratio. The decrease in FSH levels results from in-
creased frequency of GnRH pulses and chronic elevation 
of estrone (peripheral aromatization of androstenedione) 
and normal or slightly increased levels of inhibin B, de-
rived from small ovarian follicles10. 
PCOS has been considered as a complex disorder, with 
interaction of genetic variants and environmental factors 
that can interact, combine and contribute to its pathophys-
iology6. Studies have been developed to identify genetic 
variants involving the regulation of gonadotropin secre-
tion and action, insulin, energy and weight regulation, in 
addition to androgen synthesis and action1. 
An association between glucose intolerance and hyper-
androgenism was first recognized by Archard and Thiers 
in 1921, when they described the case of a diabetic woman 
with a beard1. Insulin resistance with compensatory hy-
perinsulinemia is now recognized as one of the key factors 
in this syndrome11,12. Approximately 35% of women with 
PCOS also have impaired glucose tolerance and 7% to 10% 
meet the criteria for type 2 diabetes. The excess insulin ac-
tion would be exerted by a direct action on ovarian theca 
cells via IGF-1 receptor or insulin itself, or by decrease in 
the hepatic production of IGF-binding protein (IGFBP), 
increasing the bioavailability of IGF-1 and IGF-2, in addi-
tion to stimulating cytochrome P450c17α, which increases 
ovarian and adrenal androgen production13.  
Insulin and LH act synergistically, stimulating ovar-
ian androgen production. Obesity is a common feature in 
PCOS, representing another mechanism for the develop-
ment of insulin resistance14,15. 
Insulin resistance and hyperinsulinemia are important 
in the pathophysiology of PCOS, but about 25% to 50% 
of these women do not exhibit these alterations, leading 
to the conclusion that insulin resistance and hyperinsu-
linemia are not primary causes or a pathogenic factor of 
all women with PCOS1. 
Ovarian dysfunction (anovulation or low progesterone 
production) in women with PCOS may increase the risk of 
miscarriage16. While anovulation is an obvious cause of in-
fertility in PCOS, emerging data suggest that endometrial 
receptivity also contribute to infertility3.
The occurrence of spontaneous ovulation in spani-
omenorrheic women with PCOS does not necessarily 
lead to an increase in endometrial receptivity, especially 
in cases of fertilization programs17. On the other hand, in-
fertility treatment with ovulation induction agents such as 
clomiphene citrate has shown disappointing results, with 
low pregnancy rates16. This fact is perhaps best illustrated 
with in vitro fertilization (IVF), where success rates also 
remain low in spite of the excellent quality of transferred 
embryos. This suggests that anovulation is not the only 
cause of infertility18, implying that endometrial receptivity 
might have a crucial role in the establishment and devel-
opment of pregnancy in women with PCOS. 
This article aims at reviewing the endometrial aspects 
of the “window of implantation” in normal endometrium 
and in women with polycystic ovary syndrome, focusing 
mainly on adhesion molecules. 
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METHODS
We conducted a search at http://www.ncbi.nlm.nih.gov/
pubmed/ electronic database using the following key-
words: (I) “implantation”, (II) “implantation AND PCOS”, 
(III) “implantation markers”, (IV) “endometrium”, (V) 
“polycystic ovarian syndrome AND endometrium”, (VI) 
“implantation window”. 
The initial selection of articles was based on their ti-
tles and abstracts, analyzing the full texts of those related 
to the subject. A total of 105 publications were retrieved 
from this search, excluding repetitions, and we selected for 
analysis the ones considered more relevant by the authors 
of this review.
RESULTS
NORMAL ENDOMETRIAL MORPHOLOGY
The endometrium is the mucous membrane lining the 
uterine cavity, with an embryonic origin of the fusion of 
the Mullerian ducts, around the 20th week of gestation. The 
surface is covered with simple columnar epithelium, which 
is in deep contact with endometrial stroma and glandu-
lar system. It has an essential role in reproduction and is 
considered one of the most complex tissues in the body, 
responding to cyclical changes in estrogen and progester-
one in the ovarian menstrual cycle, as well as the complex 
interaction between autocrine and paracrine factors1. 
The description of menstrual physiology is developed 
based on specific anatomical and functional changes in the 
glands, blood vessels and endometrial stroma. This distri-
bution occurs in a simplified form in the phases: prolifera-
tive (early, middle and late) and luteal or secretory phase 
(early, middle and late)19. The whole process constitutes 
an integrated evolution cycle of endometrial growth and 
regression, which is repeated throughout the female repro-
ductive life20,21.  
The proliferative phase is associated with follicular 
growth and increased estrogen secretion, leading to en-
dometrial reconstruction. Mitoses become prominent and 
pseudostratification is observed. All tissue components 
(glands, stromal and endothelial cells) show proliferation, 
with DNA nuclear and RNA cytoplasmic syntheses, which 
peak on days 8-10 of the cycle, reflecting maximum con-
centration of estrogen receptors in the endometrium22. 
An important characteristic of this phase is the increase 
in ciliated cells and cells with microvilli, necessary for the 
mobilization and distribution of endometrial secretions. 
The microvilli are cytoplasmic extensions of endometrial 
epithelial cells in response to estradiol and have the func-
tion to increase the active cell surface23.  
The first morphological sign that ovulation has oc-
curred is the appearance of intracytoplasmic glycogen vac-
uoles in the glandular epithelium, around the 18th day of 
the menstrual cycle. The glandular cells become tortuous 
and exhibit a nucleolar channel system within them, due 
to progesterone. The vessels become more spiraled; then 
the active secretion of glycoproteins and peptides oc-
curs in the endometrial cavity. Plasma transudation and 
circulation immunoglobulins are also sent to the region, 
through binding proteins produced by epithelial cells. The 
secretory peak is reached seven days after the peak of go-
nadotropins through the cycle, coinciding with the time 
of blastocyst implantation. The proliferation ceases three 
days after ovulation, with a decline in mitosis and DNA 
synthesis due to progesterone interference with the estro-
gen receptor expression24. 
The secretory phase shows signs of the combined reac-
tion of estrogen and progesterone activity on the endome-
trium. Progesterone stimulates the 17-β-hydroxysteroid 
dehydrogenase and sulfotransferase, which converts estra-
diol to estrone sulfate, and this is rapidly excreted from the 
cell1. Progesterone can inhibit specific genes that undergo 
cyclical changes during the menstrual cycle and also an-
tagonize the stimulatory action of many oncogenes that 
are likely to mediate estrogen-induced growth. The end 
result is the stability of the endometrial lining and, conse-
quently, the prevention of hyperplastic states1,25.    
The luteal phase is the most widely studied and the his-
tological changes are of clinical importance, serving as a 
guideline for the diagnosis of imperfect ovulation, unsuit-
able for the process of implantation. The early luteal phase 
(day 15) is characterized by the presence of glycogen-rich 
secretory vacuoles below the nucleus. In the middle secre-
tory phase, the vacuoles are located near the lumen of the 
glands and the nuclei are located in the basal position and 
there is secretion in the glandular lumen as well as stro-
mal edema. The endometrial thickness reaches 6-8 mm. In 
the late luteal phase, alterations occur in the stroma with 
prominent and dilated arterioles, reaching up to the sur-
face layer and the endometrium is called pre-deciduous. 
The absence of pregnancy determines the involution of the 
corpus luteum with decreasing levels of estrogen and pro-
gesterone and the onset of a menstrual period1.  
Adequate levels of these hormones are important for 
the harmonic endometrial development, both glandular 
and stromal, enabling receptivity for the blastocyst im-
plantation. In the absence of adequate endometrial prepa-
ration, there will be several infertility possibilities26. 
Noyes et al.27 examined the histological characteristics 
of endometrial biopsies performed during 8,000 spontane-
ous cycles in 300 women and established the criteria for 
endometrial dating, which were accepted as the gold stan-
dard for endometrial receptivity, detecting abnormalities 
in the latter. This classic study is still much used for the 
chronological analysis of endometrial alterations; how-
ever, deficiencies have been identified. The dating is more 
specific in the early and late luteal phases, but not during 
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the period of the “window of implantation”, demonstrating 
few histological parameters and great inter-observer vari-
ability, especially in infertile women in this cycle phase28. 
Recent gene expression studies in endometrial tissue 
have shown that some genes present in the proliferative 
phase of the menstrual cycle are essentially related to DNA 
replication, leading to cell proliferation and remodeling. 
After ovulation, with the production of progesterone, the 
endometrium undergoes a series of changes, including in-
hibition of cell proliferation, DNA synthesis and mitotic 
activity, initiating cellular differentiation, which is related 
to the preparation of the endometrium for potential em-
bryo implantation. The epithelial tissue proliferation in-
hibition is related to genes regulated by progesterone, 
including the down-regulation of estrogen receptor and 
up-regulation of the estrogen-metabolizing enzymes such 
as 17-β-hydroxysteroid dehydrogenase, which effectively 
minimizes estrogen action on this cell type. Moreover, 
progesterone is related with the regulation of androgen re-
ceptor (AR) in the epithelium and in the stroma, seven to 
ten days after ovulation, where the endometrium becomes 
receptive to embryo implantation during the period called 
the “window of implantation”9.
WINDOW OF IMPLANTATION
The embryo implantation represents the most critical step 
in the reproductive process in many species. It consists in 
a biological phenomenon, in which the blastocyst binds 
closely to the endometrial surface to form the placenta, 
which provides an interface between fetal and maternal 
circulation29,30. The implantation requires a receptive en-
dometrium and an embryo at the blastocyst stage, as well 
as an interaction between both31. The existing literature 
data are still scarce on the endometrium and the initial 
implantation mechanisms18. 
The process of implantation occurs in a sequential 
manner, where each step occurs to ensure the next one, 
leading to the establishment of pregnancy. It can be clas-
sified into three stages: apposition, adhesion and invasion. 
In the apposition phase, the embryo leaves the zona pellu-
cida overlying the endometrium and the trophoblast cells 
unsteadily attach to the surface of the receptive endome-
trial epithelium32,33. The blastocyst then closely attaches it-
self to the endometrial epithelium, at the endometrial bas-
al lamina and stromal extracellular matrix. At this point, 
the connection between the endometrium and the embryo 
is sufficiently close to resist displacement by uterine flow, 
i.e., the L-selectins present in the mucins (glycoprotein 
1 - MUC1) of the endometrium surface epithelium cells, 
which express receptive epitopes that help with blastocyst 
attachment34. 
The first sign of this reaction occurs around the 21st 
day of the menstrual cycle in humans and coincides with 
an increase in vascular permeability at the site of blasto-
cyst attachment. Subsequently, the blastocyst penetration 
occurs, invading the stroma to establish a relationship 
with the maternal vasculature, and although this activity 
is mainly controlled by the trophoblast, the decidua also 
limits the extent of invasion3,35.
Implantation occurs during a limited period between 
the 20th and 24th days of the menstrual cycle, known as 
“window of implantation”36. This process involves a com-
plex sequence of events that is crucial to establish preg-
nancy. Many molecular mediators, under the influence of 
ovarian hormones, have been postulated to be involved 
in this fetal-maternal interaction26. Morphofunctional al-
terations during this period may prevent or hinder the im-
plantation. For this reason, the study of the endometrium 
at this phase is important to improve the mechanisms in-
volved in the maternal-embryonic interaction3.   
During the window of implantation, endometrial 
stromal cells undergo a decidualization process due to 
progesterone, a process that is characterized by changes 
in the cytoskeleton (down-regulation of smooth muscle 
actin) and up-regulation of prolactin, of the insulin-like 
growth factors (IGF), IGF-binding proteins (IGFBPs), 
insulin and relaxin receptors, among others. The decidu-
alization process is important to regulate trophoblast in-
vasion and establish a suitable environment of cytokines 
and immunomodulators in the stroma during implanta-
tion. In the absence of embryo implantation, withdrawal 
of estrogen and progesterone initiates important endome-
trial events, like vasomotor reactions, cell apoptosis and 
increased metalloproteinase and prostaglandin produc-
tion, resulting in the shedding of the endometrial tissue 
and menstruation3,37. 
Many molecules have been characterized on the en-
dometrial or embryo surface, but the precise function of 
each one remains unknown. Researchers have explored 
several signaling proteins such as interleukins, receptors 
and ligands, cytokines and growth factors to determine 
how the embryo implants in the endometrium. A better 
understanding of the molecular involvement in implanta-
tion will allow the knowledge of blastocyst implantation 
failures in the endometrium18,26.   
The endometrium receptivity consists in the acquisi-
tion of adhesion ligands associated with fewer inhibitory 
components, which could form a barrier to implantation29. 
The family of cell adhesion molecules is comprised 
of four members: the integrins, cadherins, selectins and 
immunoglobulins. The surface ligand, usually glycopro-
teins, mediates cell-to-cell adhesion and has as classical 
function the maintenance of tissue integration, wound 
healing, cell migration and tumor metastasis26. A model 
shown in the literature is the possibility that the embryo 
expresses L-selectin on its surface and the endometrium 
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expresses appropriate ligands and integrins. This mecha-
nism mimics the attack of other cells, including leuko-
cytes to sites of inflamed endothelium18.    
The integrins, cell adhesion molecules (CAMs) are 
considered good markers of endometrial receptivity and 
vital to cell communication. They constitute a family of 
glycoproteins, formed by the two different non-covalent 
bonds: α and β subunits. Integrins participate in cell ma-
trix and cell-to-cell adhesion in many physiological pro-
cesses, such as embryological development, hemostasis, 
thrombosis, wound healing, immune and non-immune 
defense mechanisms and oncogenic transformation. A va-
riety of integrins has been demonstrated in the lumen of 
glandular endometrial epithelium38. 
An increase in integrins α1 β1, α4 β1 and αVβ3 has 
been described in the endometrium in the midluteal 
phase (20th -24th day of the menstrual cycle), and the ex-
pression of subunit β3 showed no increase before the 19th 
day, which has been proposed as an endometrial blasto-
cyst receptor25. They undergo hormonal influences, where 
high estrogen levels inhibit the expression of integrins and 
increases progesterone. Integrins have been expressed by 
the trophoblast at the time of implantation39, showing the 
possibility of a sandwich model in embryonic adherence26. 
Cadherins constitute a group of cell surface transmem-
brane glycoproteins responsible for the calcium-depen-
dent cell-to-cell adhesion mechanism. They are divided 
into sub-classes E, P and N-cadherins. Regarding implan-
tation, subunit E-cadherin is the most studied and is locat-
ed in the lateral plasma cell membrane, important for the 
junction between epithelial cells40. Studies in mouse em-
bryos have shown that E-cadherin gene mutations result 
in pre-implantation defects41. The role of this protein in 
human implantation is not known, but its levels have been 
shown to be increased in the luteal phase42, although no 
variations have been demonstrated in the menstrual cycle 
by immunohistochemistry studies43. 
In vitro studies with Ishikawa cell cultures have shown 
a transient increase in intracellular calcium triggered by 
calcitonin, suppressing the expression of E-cadherin at the 
cell contact site44. Progesterone induces calcitonin expres-
sion in the endometrial epithelium in the middle secretory 
phase of the menstrual cycle45, probably by regulating the 
expression of E-cadherin. It is possible that E-cadherin has 
a dual role: in the initial phase, it is required for cell adhe-
sion and at the time of implantation, it decreases to allow 
blastocyst invasion26. 
Selectins are glycoproteins that also belong to the CAM 
family and include P-selectins, L-selectins and E-selectins. 
L-selectin is important for the process of human implan-
tation and consists of a large glycosylated extracellular 
domain and a small cytoplasmic tail46. They are known 
to play a role in transendothelial leukocyte migration47. 
The adhesion system of selectins is well established in the 
maternal-fetal interface. On the side of the blastocyst, L-
selectin has been observed and on the maternal side, the 
expression of selectin ligands such as MECA-79 or Heca-
452 is increased during the window of implantation48. 
The immunoreactivity of the L-selectin ligand MECA-79 
seems to be stronger in the epithelial lumen than in glan-
dular epithelium49. The physiological importance of the 
interaction between L-selectin and its oligosaccharide li-
gands was investigated in the endometrium48 and tropho-
blastic cells, suggesting that this process could constitute 
the initial step in blastocyst implantation50. The role of L-
selectin is regulated by a variety of mechanisms including 
gene transcription and associations acting on the cytoskel-
eton, in addition to its topographic distribution by increas-
ing or decreasing the free cell surface. Despite research ad-
vances, little is known about the involvement of selectins 
in embryonic implantation, suggesting that its participa-
tion occurs at the initial stages, by signaling the best place 
for blastocyst implantation into the uterine wall26.     
Among the components of the CAM family, immuno-
globulins are the most extensive. The intercellular adhesion 
molecule-1 (ICAM-1 or CD54) is a transmembrane glyco-
protein that belongs to the immunoglobulin superfamily 
and is expressed on the surface of various cell types such 
as fibroblasts, leukocytes, endothelial and epithelial cells. 
This molecule is regulated by inflammatory and nonin-
flammatory cytokines. The interaction of ICAM-1 is es-
sential for the transendothelial migration of leukocytes 
and several immunological functions51. It has been well 
established that the endometrium, under normal circum-
stances, contains a large population of leukocytes, includ-
ing macrophages, T-lymphocytes and granulocytes, which 
is important in many physiological mechanisms such as 
decidualization52, menstruation and childbirth53. This 
population of leukocytes expresses ICAM-1 in the en-
dometrium and was found in both epithelial and stroma 
cells, suggesting that this protein may play a role in the 
pathophysiology of the endometrium54.  
The relationship between the expression of ICAM-1 
and recurrent pregnancy loss has been investigated, hav-
ing been identified in endometrial cells in the luteal phase 
of patients with and without unexplained pregnancy loss55. 
Although ICAM-1 has not been shown to be indispens-
able in the initial steps of the interaction between the blas-
tocyst and the endometrium, it can participate indirectly in 
this process by interacting with the immune system56. 
HOX genes are essential for the proliferation, differ-
entiation and endometrial receptivity by mediating some 
sex steroid functions during each reproductive cycle. The 
mRNA of the HOXA-10 and HOXA-11 are expressed in 
epithelial and endometrial stroma cells, especially in the 
middle and late secretory phases, remaining at high levels 
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after embryonic implantation3. Some morphological and 
molecular markers, which are specific to the window of 
implantation are regulated by HOX genes, such as pino-
pods, β3-integrin and IGFBP-I57.   
Several benign diseases, including PCOS, are associ-
ated with decreased cyclical fertility and uterine receptiv-
ity3,18. In spite of technological advances in assisted repro-
duction techniques, allowing the selection of top-quality 
embryos, the implantation rate is still low and has not 
increased enough in recent decades3,58. Uterine receptivity 
plays a key role in establishing the success of pregnancy 
and when altered, it may limit the success of assisted re-
production techniques and contribute to infertility in cer-
tain gynecological diseases, such as PCOS18. 
ENDOMETRIUM IN POLYCYSTIC OVARY SYNDROME DURING THE 
WINDOW OF IMPLANTATION
In women with PCOS who are oligo- or anovulatory, the 
regulatory role of progesterone is suboptimal or absent, 
and this results in constant non-opposition of estrogen 
action on the endometrium3,9. Thus, endometrial growth 
and differentiation in women with PCOS are influenced by 
androgens, insulin and estrogen without progesterone op-
position. In the absence of ovulation and the effects of pro-
gesterone regulation, the endometrium does not undergo a 
secretory transformation and is constantly exposed to the 
stimulating and mitogenic effects of estradiol, which may 
lead to endometrium overgrowth, unpredictable bleeding 
patterns, hyperplasia and cancer.  
The endometrium of women with PCOS is considered 
a model of dysfunctional endometrium, demonstrating 
overexpression of androgen receptors and failing to regu-
late estrogen receptors (ERs), when compared to normal 
women59. Studies carried out in PCOS have shown differ-
ences in complements of steroid receptors and coactiva-
tors, when compared to fertile women. The endometrium, 
in this case, overexpresses androgen receptors and fails to 
regulate the ER-α (estrogen receptor, α) in the window of 
implantation59-61. 
PCOS has other common features in addition to hyper-
androgenism and ovulatory dysfunction that are not in-
cluded in the diagnostic criteria already established, such 
as abnormal secretion of gonadotropins, insulin resistance 
and metabolic abnormalities (dyslipidemia). Increased ex-
pression of AIBI coactivators (nuclear receptor coactiva-
tor 3) of the estrogen receptor and TIF2 (transcriptional 
intermediary factor 2) may enhance the estrogen activity 
in endometrial cells in PCOS59. 
The existing literature data are not very clear whether 
there is an endometrial dysfunction in PCOS, regardless 
of progesterone action. Some studies indicate that the en-
dometrial process, including cell proliferation, differentia-
tion and response to biological stimulus, could be affected 
by other factors such as cytokines and growth factors, ex-
plaining in part the poor reproductive outcomes in this 
group of women18. 
There is an obvious increase in the deregulated ex-
pression of uterine receptivity markers in the endome-
trium of women with PCOS. Studies show that in ovula-
tory patients with PCOS, the αvβ3-integrin, HOXA-10, 
HOXA-11 and the expression of insulin-like growth factor 
(IGFBP-I) binding protein is decreased during the secre-
tory phase3,60,62,63. Literature considerations on the expres-
sion and regulation of αVβ3-integrin show that this pro-
tein may represent a marker for the human implantation 
process.  
The expression of HOXA-10 in vitro has shown to be 
directly decreased by testosterone, suggesting that andro-
gen decrease could improve endometrial responsiveness3. 
Studies have shown decreased expression of αvβ3-integrin 
and overexpression of estrogen activity markers (Cyr61) in 
the window of implantation64.
Another study also showed that the dysfunction in the 
implantation would be related to dysfunctional endome-
trial alterations in women with PCOS18,37. 
FINAL CONSIDERATIONS 
The endometrial modifications that occur during the win-
dow of implantation require subtle collaboration of a large 
number of different factors and although some have been 
described, their individual role in the development of the 
endometrium is not yet fully understood. Studies in hu-
mans have been mostly developed in cycles outside of the 
pregnancy and genetic suppression experiments (animal 
or in vitro) provide indirect evidence.
The exact mechanism of implantation failure is still 
poorly understood, particularly in diseases such as PCOS. 
Although the quality of embryos is an important determi-
nant, the endometrium, through a temporary and coor-
dinated receptivity mechanism, synchronized between its 
cells and those of the embryo, has an unquestionable con-
tribution to the success of pregnancy.
The reduced expression of uterine receptivity mark-
ers and lack of regulation of the expression and activity of 
steroid receptors can contribute to the low pregnancy rate 
observed in women with PCOS; however, whether these 
alterations are due to inadequate progesterone action or 
increased insulin and androgen action remains to be clari-
fied. 
CONCLUSION
Endometrial receptivity seems to be the main limiting fac-
tor for the establishment of pregnancy in a large number 
of gynecological disorders, including PCOS and treatment 
to improve implantation rates is likely to be taken towards 
that direction.
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The perspectives consist in the development of tools, 
such as regulation of transcription factors of endometrial 
proteins or gene therapy to improve uterine receptivity in 
infertile women with PCOS and thus, increase implanta-
tion rates in this population. 
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